

David Ternant

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9105896/david-ternant-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

2,378
citations

24
h-index

48
g-index

79
ext. papers

2,757
ext. citations

4.7
avg, IF

4.6
L-index

#	Paper	IF	Citations
73	Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3160-3169	1.9	
72	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
71	A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. <i>Bioanalysis</i> , 2021 , 13, 565-574	2.1	0
70	Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	
69	Food and lipid intake alters the pharmacokinetics of cyclosporine in kidney transplants. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 446-454	3.1	
68	Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1594-1595	3.8	0
67	Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2236-2246	3.8	3
66	Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives. <i>Vaccines</i> , 2021 , 9,	5.3	1
65	Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 210-219	6.1	0
64	Infliximab Treatment Does Not Lead to Full TNF- α Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
63	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
62	Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3372-3374	3.8	1
61	Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. <i>RMD Open</i> , 2020 , 6,	5.9	21
60	Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 857-874	6.2	16
59	Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. <i>Clinical Nutrition</i> , 2020 , 39, 3319-3330	5.9	2
58	P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment. <i>Cancers</i> , 2020 , 12,	6.6	13
57	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 519-530	6.2	5

56	Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 37-49	6.2	13
55	CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2747-2758	3.8	8
54	17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia 2019 , 7, 22		8
53	Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2002-2010	3.8	10
52	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 169-187	6.2	20
51	New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 722-728	3.8	3
50	Development and validation of an ELISA to study panitumumab pharmacokinetics. <i>Bioanalysis</i> , 2018 , 10, 205-214	2.1	3
49	Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab. <i>European Journal of Cancer</i> , 2018 , 92, 119-120	7.5	3
48	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018 , 103, e356-e359	6.6	5
47	Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1173-1184	6.2	10
46	Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1745-1754	4.5	7
45	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1773-1781	3.8	23
44	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017 , 129, 2616-2623	2.2	57
43	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 339-343	3.2	9
42	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 322-326	3.2	18
41	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 364-369	3.2	16
40	Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. <i>Bioanalysis</i> , 2017 , 9, 1227-1235	2.1	7
39	A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. <i>BMC Cancer</i> , 2017 , 17, 220	4.8	11

38	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 635-647	6.2	16
37	Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 108-113	9.5	18
36	Gota et al. on their article "the pharmacokinetics of Reditux[la biosimilar of rituximab". <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1317-1318	3.5	2
35	Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 567-72	3.2	12
34	CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. <i>Transplant International</i> , 2016 , 29, 184-95	3	5
33	Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1381-1394	6.2	34
32	A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 253-5	2.8	9
31	Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, e151-5	2.2	25
30	IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. <i>Journal of Immunology</i> , 2016 , 196, 607-13	5.3	41
29	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 941-8	3.8	22
28	The underlying inflammatory chronic disease influences infliximab pharmacokinetics. <i>MABs</i> , 2016 , 8, 1407-1416	6.6	37
27	Pharmacokinetics of adalimumab in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1155-7	2.8	24
26	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1107-23	6.2	72
25	Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. <i>MABs</i> , 2015 , 7, 630-7	6.6	18
24	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. <i>MABs</i> , 2015 , 7, 1205-11	6.6	49
23	A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1541-2	2.8	12
22	Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 286-97	3.8	51
21	Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 551-62	6.2	43

20	Towards an individualised target concentration of adalimumab in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1428-9	2.4	21
19	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 118-28	3.8	57
18	Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 26-34	1.9	9
17	Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. <i>Transplant Immunology</i> , 2013 , 28, 120-6	1.7	22
16	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 597-605	3.8	19
15	Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 55-65	3.8	40
14	Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 948-55	27.4	242
13	Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R82	5.7	31
12	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011 , 13, R105	5.7	109
11	Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 6329-37	12.9	77
10	An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 647-52	3.2	28
9	Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 232-6	3.2	51
8	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 561-73	3.8	17
7	An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 597-601	3.2	30
6	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009 , 113, 3765-72	2.2	102
5	Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcγRIIIa genetic polymorphism. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 60-8	3.8	8
4	Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. <i>Gastroenterology</i> , 2008 , 134, 1861-8	13.3	390
3	Infliximab pharmacokinetics in inflammatory bowel disease patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 523-9	3.2	143

- 2 An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. *Therapeutic Drug Monitoring*, **2006**, 28, 169-74 3.2 86
- 1 Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. *Expert Opinion on Biological Therapy*, **2005**, 5 Suppl 1, S37-47 5.4 87